Eiger BioPharmaceuticals, Inc. (EIGRQ)

Eiger BioPharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	19	10	52	176	400	365
Market Cap Growth	-80.84%	-80.84%	-70.51%	-55.90%	9.55%	88.12%
Enterprise Value	34	26	-7	120	303	302
PE Ratio	-	-0.13	-0.54	-5.20	-6.15	-5.19
PS Ratio	1.17	0.63	3.86	14.52	-	-
PB Ratio	-0.69	-0.69	0.94	2.44	4.21	6.46
P/FCF Ratio	-0.13	-0.13	-0.62	-2.47	-6.30	-5.69
P/OCF Ratio	-0.13	-0.13	-0.63	-2.47	-6.33	-5.74
EV/Sales Ratio	2.17	1.63	-0.50	9.89	-	-
EV/EBITDA Ratio	-0.37	-0.37	0.07	-4.07	-4.99	-4.55
EV/EBIT Ratio	-0.37	-0.37	0.07	-3.96	-4.94	-4.52
EV/FCF Ratio	-0.34	-0.34	0.08	-1.68	-4.78	-4.72
Debt / Equity Ratio	-2.85	-2.85	0.73	0.45	0.34	0.57
Debt / EBITDA Ratio	-0.60	-0.60	-0.44	-1.10	-0.53	-0.49
Debt / FCF Ratio	-0.55	-0.55	-0.48	-0.46	-0.51	-0.50
Quick Ratio	0.51	0.51	4.01	3.06	7.75	5.60
Current Ratio	0.71	0.71	4.68	3.46	8.29	5.92
Asset Turnover	0.24	0.24	0.09	0.08	0	0
Interest Coverage	-12.71	-12.71	-22.42	-8.51	-17.10	-19.63
Return on Equity (ROE)	-869.80%	-869.80%	-116.00%	-34.20%	-89.80%	-105.20%
Return on Assets (ROA)	-112.70%	-112.70%	-66.60%	-22.60%	-54.70%	-62.30%
Return on Capital (ROIC)	-268.41%	-268.41%	-97.10%	-73.32%	-48.73%	-77.66%
Earnings Yield	-404.99%	-752.31%	-186.08%	-19.23%	-16.27%	-19.25%
FCF Yield	-404.01%	-750.49%	-160.26%	-40.43%	-15.87%	-17.56%
Buyback Yield / Dilution	-6.39%	-6.39%	-22.64%	-20.61%	-23.51%	-67.12%
Total Shareholder Return	-6.39%	-6.39%	-22.64%	-20.61%	-23.51%	-67.12%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).